Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

BACKGROUND: In the phase 3 METEOR trial (NCT01865747), cabozantinib significantly improved progression-free survival, overall survival, and objective response rate compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy. A statistically signif...

Descripción completa

Detalles Bibliográficos
Autores principales: Motzer, Robert J., Escudier, Bernard, Powles, Thomas, Scheffold, Christian, Choueiri, Toni K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943250/
https://www.ncbi.nlm.nih.gov/pubmed/29576624
http://dx.doi.org/10.1038/s41416-018-0061-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943250/
https://www.ncbi.nlm.nih.gov/pubmed/29576624
http://dx.doi.org/10.1038/s41416-018-0061-6

Ejemplares similares